IP Library Granted Patent US 7,951,907
Granted Patent B2
US 7,951,907 · App. 12/618,485 · Granted May 31, 2011

Circovirus sequences associated with piglet weight loss disease (PWD)

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,951,907
App. No.
12/618,485
Granted
May 31, 2011
Kind
B2
Abstract

The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.

Claims (7)

1. A vaccine comprising: a pharmaceutically or veterinarily acceptable carrier; and an isolated immunogenic porcine circovirus Type B (PCVB) polypeptide having at least 90% identity to the sequence of SEQ ID NO: 26, wherein the polypeptide induces an immunological response in a porcine against PCVB.

2. The vaccine according to claim 1 , wherein the isolated immunogenic porcine circovirus Type B (PCVB) polypeptide has at least 95% identity to the sequence of SEQ ID NO: 26.

3. The vaccine according to claim 1 , wherein the immunogenic PCVB polypeptide has at least 98% identity to SEQ ID NO: 26.

4. The vaccine according to claim 1 , wherein the immunogenic PCVB polypeptide has the sequence of SEQ ID NO: 26.

5. The vaccine according to any one of claims 1 - 4 , wherein the polypeptide is generated by recombinant production.

6. The vaccine according to any one of claims 1 - 4 , wherein the polypeptide is generated by chemical synthesis.

7. The vaccine according to any one of claims 1 - 6 , further comprising an adjuvant.

Assignments (7)
ADDRESS CHANGE OF ASSIGNEE Recorded Jun 5, 2017
From: ZOETIS SERVICES LLC
To: ZOETIS SERVICES LLC
Reel/Frame 042687/0541 →
MERGER Recorded May 13, 2015
From: ZOETIS W LLC
To: ZOETIS SERVICES LLC
Reel/Frame 035651/0884 →
CHANGE OF NAME Recorded Mar 27, 2013
From: PAH W LLC
To: ZOETIS W LLC
Reel/Frame 030091/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2013
From: WYETH LLC
To: PAH W LLC
Reel/Frame 029900/0001 →
CHANGE OF NAME Recorded May 20, 2010
From: WYETH
To: WYETH LLC
Reel/Frame 024411/0350 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2009
From: JESTIN, ANDRE; ALBINA, EMMANUEL; LECANN, PIERRE; BLANCHARD, PHILIPPE; HUTET, EVELYNE; ARNAULD, CLAIRE; TRUONG, CATHERINE; MAHE, DOMINIQUE; CARIOLET, ROLAND; MADEC, FRANCOIS
To: AGENCE FRANCAISE DE SECURITE SANITAIRE DES ALIMENTS
Reel/Frame 023517/0264 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2009
From: AGENCE FRANCAISE DE SECURITE SANITAIRE DES ALIMENTS
To: WYETH
Reel/Frame 023517/0278 →